Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corporation (NASDAQ:UTHR), filed a Form 4 on September 11, 2026, disclosing stock option exercises and share disposals that occurred on September 10, 2026, pursuant to a pre-arranged Rule 10b5-1 trading plan.
Key Highlights
- Option exercise: 9,500 stock options were exercised at a conversion price of $117.76 per share, held indirectly through a family trust.
- Ten separate disposal transactions: Shares acquired from the option exercise were sold in ten coded "S" transactions on September 10, 2026, at weighted average prices ranging from $498.44 to $508.8043.
- Beneficial ownership after transactions: Shares held indirectly by the reporting trust fell to 324,443 following the final reported sale transaction.
- Pre-arranged plan: All transactions were executed under a 10b5-1 trading plan adopted by Rothblatt on November 7, 2025.
- Plan scope: The plan covers up to 1,734,410 stock options, all expiring March 15, 2027, and will continue until the earlier of full exercise or December 31, 2026.
- Options vesting: The exercised options vested in equal one-third installments on March 15, 2021, 2022, and 2023, according to the filing.
Rothblatt's Option Exercise and Share Sales at United Therapeutics
According to the filing, Martine A. Rothblatt, who serves as both Chairperson and CEO of United Therapeutics Corporation, exercised 9,500 stock options on September 10, 2026, at an exercise price of $117.76 per share. The options were held indirectly through a family trust in which Rothblatt shares investment power and in which Rothblatt and immediate family members are beneficiaries, as the filing describes. Following the exercise, the trust held 333,943 shares of common stock.
Rothblatt then disposed of shares through ten separate sale transactions on the same date, with weighted average prices ranging from $498.44 per share to $508.8043 per share. Each of these transactions was executed in multiple trades, and the filing notes that full information on the number of shares and prices at which each transaction was effected will be provided upon request to the SEC staff, the issuer, or a security holder. After the final reported sale of 280 shares at a weighted average price of $508.8043, the trust's beneficial ownership stood at 324,443 shares of common stock.
The filing states that all activity was conducted under a pre-arranged 10b5-1 trading plan adopted on November 7, 2025. That plan will continue until the earlier of the exercise of 1,734,410 stock options, all of which expire on March 15, 2027, or December 31, 2026. United Therapeutics is a biopharmaceutical company focused on the development and commercialization of products for patients with chronic and life-threatening conditions. The filing also discloses that Rothblatt holds 461,410 stock options indirectly through a family trust following the reported exercise, and maintains additional share positions directly and indirectly across several other family trusts and through a spousal interest, as detailed in Table I of the filing.
What Was Disclosed
The filing reported the exercise of 9,500 stock options and ten share disposal transactions by CEO Martine A. Rothblatt on September 10, 2026, all conducted under a pre-arranged 10b5-1 plan adopted November 7, 2025, with shares and options held indirectly through family trusts.




Please wait processing your request...